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Abstract 
Increased levels of glucagon in type 2 diabetes are well known and, until now, have been considered deleterious. 
However, glucagon has an important role in the maintenance of both heart and kidney function. Moreover, in the 
past, glucagon has been therapeutically used for heart failure treatment. The new antidiabetic drugs, dipeptidyl 
peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors, are able to decrease and to increase gluca-
gon levels, respectively, while contrasting data have been reported regarding the glucagon like peptide 1 receptors 
agonists. The cardiovascular outcome trials, requested by the FDA, raised some concerns about the possibility that the 
dipeptidyl peptidase-4 inhibitors can precipitate the heart failure, while, at least for empagliflozin, a positive effect has 
been shown in decreasing both cardiovascular death and heart failure. The recent LEADER Trial, showed a significant 
reduction of cardiovascular death with liraglutide, but a neutral effect on heart failure. A possible explanation of the 
results with the DPPIV inhibitors and empagliflozin might be related to their divergent effect on glucagon levels. Due 
to unclear effects of glucagon like peptide 1 receptor agonists on glucagon, the possible role of this hormone in the 
Leader trial remains unclear.
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Glucagon and glucose metabolism
Glucagon was identified as a pancreatic contaminant at 
the time of the discovery of insulin; it received the name 
of glucagon (GLUCose AGONist substance) because 
it was thought to be a glucose agonist [1]. This “long-
known opponent” [2] of insulin in glucose homeostasis is 
a 29-amino acid hormone secreted by the α-cells of the 
pancreas. Its secretion is strictly correlated to the blood 
glucose levels: low levels of blood glucose in the fasting 
state determine secretion of glucagon and inhibit insulin 
secretion. Consequently, glucagon secretion restores glu-
cose levels through hepatic glycogenolysis and gluconeo-
genesis, along with inhibition of glycogenesis.
Glucagon secretion is regulated by insulin and soma-
tostatin, (as the main paracrine/endocrine inhibitors), 
glucose, glucagon-like peptide-1 (GLP-1), amylin, leptin, 
fatty acids, ketone bodies—all inhibiting glucagon secre-
tion, glucose-dependent insulinotropic peptide (GIP), 
amino-acids (as l-arginine, leucine)—stimulating gluca-
gon secretion, and by the autonomic nervous system. 
Meier et al. [3] demonstrated that also glucagon-like pep-
tide-2 (GLP-2) stimulates glucagon secretion.
Some of the drugs often used in patients with type 2 
diabetes (T2D), such as furosemide or acetylsalicylic 
acid, may influence prostaglandins (PG) synthesis, 
mainly PGE, which in turn control glucagon release [4]. 
Also, stressful stimuli, as hypovolemia, stimulate gluca-
gon secretion [5].
It has been known for a long time that large meals con-
taining only proteins increase whereas meals rich in car-
bohydrates decrease, glucagon secretion [6].
Insulin modulates glucagon secretion while physiologi-
cal levels of glucagon stimulate insulin secretion [1, 2, 7].
Glucagon receptors are mainly located in the liver 
(hepatocytes and Kupfer cells) and kidney. They may be 
found also, at a lesser degree, in the endocrine pancreas 
(β- and α-cells), heart, adipocytes, gastrointestinal (GI) 
tract, brain, adrenal glands, lymphoblasts, retina and 
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placenta [1, 2, 8]. Intense physical exercise, hypercorti-
cism and stimulation of the ventro-medial hypothalamus 
determine an increase of glucagon secretion [6].
Glucagon beyond glucose metabolism
Glucagon has been used not only as an inotropic agent 
and vasodilator but also as an inhibitor of the smooth 
muscle activity of the GI tract (including as an aid for 
radiological examinations) [9].
Pleiotropic actions of glucagon
Today, besides its actions on glucose metabolism, gluca-
gon is known to have other relevant effects [2, 3, 8]:
  • On lipid metabolism: decreased plasma cholesterol, 
total esterified fatty acids, decreased hepatic synthe-
sis of triglycerides and apolipoproteins. In addition, 
glucagon determines lipolysis in white adipose tissue.
  • Increased ketone-body production and fatty acid oxi-
dation.
  • Increased energy expenditure and thermogenesis by 
an increased oxygen consumption, blood flow and 
heat production in brown adipose tissue.
  • Decreased food intake, with reduction of meal size, 
increased satiation (possibly mediated through ghre-
lin) and decreased gastric emptying.
  • Regulation of secretion of other hormones, such as 
insulin, ghrelin, somatostatin, cortisol and growth 
hormone.
  • Retinal function: loss of retinal function and of vis-
ual acuity and retina cells death have been described 
after the disruption of glucagon receptor (gcgr) gene 
and were directly correlated with the degree of hypo-
glycaemia in rodent models.
The above-described effects make glucagon an attrac-
tive therapeutic target in obesity, eating and lipid disor-
ders [3].
Glucagon and the heart
Along with the key actions of glucagon in glucose home-
ostasis, since the 60s, (after Unger adapted the radioim-
munoassay to measure glucagon), human and animal 
experiments have highlighted direct actions on the heart 
of physiological levels of glucagon [3, 7].
In humans it has been proved that acute glucagon 
administration exerts a positive action on cardiovascu-
lar performance either increasing cardiac index, either 
decreasing peripheral vascular resistances [10]. Moreo-
ver, the positive enhancement of cardiovascular perfor-
mance is comparable to what has been observed in cat 
and dog, with persistence of action despite beta-receptor 
blockade with propranolol [11].
In the non-failing heart, glucagon determines a rise in 
heart rate, almost without changes in cardiac output and 
auricular pressure; in the failing heart, it increases heart 
rate and cardiac output, together with a dose-dependent 
increase in coronary blood flow and oxygen consumption 
[12]. These actions of glucagon are mediated through 
cyclic AMP (cAMP).
Several factors affect glucagon actions on the heart. 
Among them, as seen above, the most important for our 
topic is heart failure (HF). In this context, the type of HF, 
its severity and chronicity are relevant [12, 13]. In fact, a 
greater severity of HF is associated with a smaller hemo-
dynamic response to glucagon. In addition, glucagon 
determines a weaker response in chronic than in acute 
HF [12, 13].
The inotropic effects of glucagon are more potent in 
the ventricle than in the atrium, [7]. It does not increase 
irritability of the myocardium and it is active in the pres-
ence of digitalis and propranolol. Thus, attempts for a 
therapeutic use of glucagon have been made in resistant 
cardiac failure, myocardial infarction, hypotension fol-
lowing cardiac operations, intoxication with β-/calcium 
channel blockers and heart block [7, 14–16].
Glucagon also facilitates the atrio-ventricular conduc-
tion and its inotropic action is accompanied by an anti-
arrhythmogenic effect (which, might be due partially 
to an increased insulin-mediated uptake of potassium 
(K+) by the myocardium following glucagon administra-
tion) [12, 14]. Glucagon has an important effect on sino 
atrial node rate [17] and the antiarrhythmogenic effect of 
glucagon has been several times reviewed [18–23].
Furthermore, glucagon is able to decrease histamine-
induced cardiac injury during reperfusion [2] and 
restores the pressure of the coronary perfusion during 
ischemic vasodilation [24].
As an inotropic agent, glucagon increases the work 
of the heart and, consequently, it increases oxygen con-
sumption, lipolysis and beta-oxidation of lipids [1]. It is 
noteworthy that both insulin and glucagon increase fuel 
availability in the heart. In animal studies, glucagon, simi-
larly to insulin, increases glycolysis and glucose oxidation 
through phosphatidylinositol 3-kinase-dependent and 
adenylate cyclase- and cAMP-independent pathways [7].
As hyperglucagonemia determines an increased availa-
bility of substrate and improves cardiovascular (CV) per-
formance (crucial in a physiological stress response), this 
hormone is considered today to be a stress hormone [5].
Glucagon and the kidney
In the kidneys, glucagon at relatively high doses, induces 
vasodilation with a concomitant increase in renal plasma 
flow (RPF), glomerular filtration rate (GFR) and elec-
trolyte excretion. These changes are more evident in 
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patients with diabetes, possibly due to the modified 
insulin:glucagon ratio; the administration of insulin, 
which normalizes this ratio, brings GFR and RPF close to 
normal values.
In respect to the electrolytes, glucagon is responsible 
of the increase of natriuresis in the fasting state. During 
starvation glucagon is increased and insulin is decreased; 
re-feeding with carbohydrates has an anti-natriuretic 
effect [12].
Glucagon determines initially a transient increase in 
plasma K+ levels (partially due to the hepatic glycog-
enolysis), followed by hypopotassemia determined by an 
increased uptake (muscles, liver) induced by insulin.
Glucagon also increases the urinary excretion of cal-
cium, phosphate and zinc [12].
The direct action of glucagon (and vasopressin) in 
protein-induced hyperfiltration is well established now 
[25]. Glucagon plays an important role in the excretion 
of nitrogen end products (increased urea synthesis in the 
liver and urea excretion in the kidney), while vasopressin 
concentrates these products in a hyperosmotic urine and 
producing water economy. In the absence of any of these 
two hormones, glomerular hyperfiltration is not possible 
[25]. In conclusion, glucagon is a relevant component of 
the close relationship between heart and kidney function, 
aiming to maintain the continuum pressure volume cir-
culatory balance.
Glucagon in type 2 diabetes
Schematically, type 2 diabetes (T2D) is characterized by: 
β-cell failure, α-cells insulin resistance and decreased 
incretin effect.
  • β-cell failure due to partial loss of β-cell mass and 
β-cell dysfunction, influenced by a genetic back-
ground and by chronic exposure to gluco- and lipo-
toxicity, amylin and advanced glycation end-products 
(AGEs).
  • α-cells insulin resistance the so called by Unger and 
Orci, “paracrinopathy” and T2D “a bi-hormonal dis-
order”. In T2D, α-cells might be resistant to the inhib-
itory effect of insulin [26] or to other β-cell secretory 
products such as zinc or γ-aminobutyric acid [7].
Consequently, T2D is characterized by fasting hyper-
glucagonemia and impaired glucose-induced glucagon 
suppression in the post-prandial state (insulin/gluca-
gon concentration inversely related in the post-prandial 
state). Mainly due to β-cell apoptosis, β/α-cell ratio is 
altered, contributing to a decreased insulin/glucagon 
ratio. Also, β-cell may de-differentiate to progenitor 
pluripotent cells that may release glucagon and somato-
statin, thus further decreasing insulin/glucagon ratio [3, 
7]. In this context, it is clear that glucagon is a key hor-
mone worsening the metabolic consequences of insulin 
deficiency [27]. Type 2 diabetes is also characterized by 
a decreased incretin effect: in T2D, glucose-dependent 
insulinotropic peptide (GIP) and GLP-1 account only for 
<20 % of the postprandial insulin response. While GLP-1 
action is relatively preserved, β-cell impairment deter-
mines a decrease in the insulinotropic action of GIP; the 
following hyperglycaemia further downregulates the GIP 
receptor in β-cells, aggravating the impairment of the 
incretin effect, creating a vicious cycle [1].
A decrease in incretin action may affect the crosstalk 
between AGEs-RAGE axis, favouring the appearance 
of complications [28]. It is worthy of interest that when 
hepatic glycogen content is low, glucagon response to 
insulin-induced hypoglycemia is reduced [29]. In this 
view, glucagon has been recently suggested as the key 
feature of type 2 diabetes [30].
New antidiabetes treatments and glucagon
The increased glucagon/insulin ratio is a key factor in 
the pathogenesis of hyperglycaemia in T2D; the lack of 
glucagon suppression in the post-prandial state leads to 
post-prandial hyperglycaemia, whereas inappropriate 
levels of glucagon in the fasting state leads to increased 
hepatic glucose production and fasting hyperglycaemia.
Consequently, addressing glucagon seemed an attrac-
tive treatment for T2D by either suppression of glucagon 
secretion or by blocking gcgr. Monoclonal glucagon anti-
bodies, glucagon receptor antagonists (peptide and non-
peptide) and molecules targeting the expression of gcgr 
have all been tested as potential treatments for T2D [7].
However, research on those agents encountered a num-
ber of major obstacles, most notably a limited efficacy, 
the risk of iatrogenic hypoglycaemia, and other safety 
issues related to lack of specificity of glucagon blockade, 
immunogenity and toxicity [31].
Interestingly, the reduction of glucagon levels should 
be one of the main mechanisms of action of some of the 
recent antidiabetes drugs (ADD) for T2D, such as GLP-1 
receptor agonists (GLP-1 RA) and inhibitors of dipepti-
dyl peptidase-4 (DPP-4i) [31].
GLP-1RA increase insulin synthesis and secretion in a 
glucose-dependent manner and decrease glucagon lev-
els probably; this latter effect could be exerted through 
somatostatin or neural regulation, as the α-cell do not 
show GLP-1 receptors [1, 31].
Additionally, GLP1-RA slow gastric empting, decrease 
appetite, induce satiety and potentially, inhibit β-cell 
apoptosis [32]. They have favorable effects on body weight 
and body composition (decreasing mainly the visceral fat) 
and plasma lipids. In animal models, long-term treatment 
with GLP1-RA also increase β-cell mass [33, 34].
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However, it has been shown that glucagon and GLP-1 
co-agonism has a significant greater efficacy than GLP-1 
RA monotherapy on body weight, body composition, 
glucose and lipid metabolism, including the reversal of 
hepatic steatosis, making this combination therapy an 
attractive and promising treatment for obesity and meta-
bolic syndrome [2].
Short-acting GLP-1 RA (exenatide and lixisenatide) 
lower mainly post-prandial glucose, partly by inhibiting 
gastric empting: conversely longer-acting molecules of 
the class (albiglutide, dulaglutide, exenatide LAR, lira-
glutide) target predominantly fasting plasma glucose 
through their insulinotropic and glucagonostatic actions 
[33, 34]. The durability of the glucagonostatic effect in 
the long-term treatment with GLP-1 RA has been inves-
tigated for liraglutide in the LIBRA trial. Quite surpris-
ingly, chronic treatment with liraglutide in patients with 
early T2D has been associated with an increased post-
challenge glucagonemia [35]. The real effects of GLP-1RA 
on glucagon probably remains to be further elucidated, 
considering that also Albiglutide does not affect glucagon 
secretion during hypoglycemia [36].
DPP-4i increase the duration of action of the endog-
enous GLP-1 through the inhibition of DPP-4 enzyme. 
Consequently, the GLP-1 levels are increased although 
the stimulation of the GLP-1 axis is not so potent as 
that determined by GLP1-RA. This action is sufficient 
to determine a moderate reduction of blood glucose, 
with no effects on body weight, no risk of severe hypo-
glycemia, and no gastrointestinal side effects. DPP-4i also 
induce an increase in circulating levels of GIP, which is 
another one of the substrates of DPP-4. The reduction in 
glucagon levels observed during treatment with DPP-4i 
results from the increase of both GLP-1 and GIP [34, 37].
Worth to mention, mainly in the context of this article, 
is that the incretins have beneficial effects on the CV sys-
tem by decreasing blood pressure, improving left ventric-
ular function and endothelium-dependent vasodilation 
and by increasing the endothelial progenitor cells [38].
SGLT-2i are the last approved class of ADD, which 
inhibit glucose reabsorption in the proximal renal tubule, 
independently of insulin secretion or action. Conse-
quently, glucose is lost in the urine and glycaemia is 
decreased [34].
Regarding glucagon secretion, in opposition with 
GLP-1 RA and DPP-4i, SGLT-2i increase plasma 
glucagon.
In the kidney, glucagon controls the rate of filtration, 
urea excretion and the reabsorption of water through 
direct and indirect mechanisms, even though its role in 
renal glucose output is unclear. In an animal model, long-
term infusion of glucagon induced hypertension, hyper-
trophy, and increased proliferation of mesangial cells [7].
A non-selective inhibitor of glucose reabsorption in 
the proximal nephrons which targets both SGLT-1 and 
SGLT-2, phlorizin, was increasing glucagon levels, an 
effect confirmed by SGLT-2i [3]. The association between 
SGLT-2 inhibition, increased endogenous glucose pro-
duction (EGP) and glucagon during euglycaemia has not 
been expected. It has been demonstrated that the SGLT-2 
transporters are expressed not only in the proximal 
tubules but also in the α-cells, but not in β-cells. The inhi-
bition of SGLT-2 directly stimulates glucagon secretion 
through the activation of KATP channel [39, 40].
Since the mechanism of action of SGLT-2i is independ-
ent of β-cells and different from that of the other exist-
ing classes of ADD, it has been suggested that SGLT-2i 
might be combined with other drug(s) and mainly with 
DPP4i; this combination therapy is well-tolerated and 
not accompanied by the most common seen side-effects: 
hypoglycaemia or weight gain. Also, DPP4i increase insu-
lin secretion and decrease glucagon; so, potentially they 
block the compensatory EGP seen with SGLT-2i and 
increase their glucose-lowering capacity [38, 41, 42].
Cardiovascular outcome trials and glucagon
After the CV safety concerns raised by some ADD either 
in development or marketed (e.g. muraglitazar, rosigli-
tazone) and by the results of some clinical trials (e.g. 
ACCORD), the US Food and Drug Administration (FDA) 
issued in 2008 the “FDA Guidance for Industry” focus-
ing on the CV risk assessment of ADD. Consequently, 
post-approval, there is the requirement to perform a CV 
outcome trial (CVOT) [43, 44], which has as primary 
endpoint major adverse cardiac events (MACE) such 
as: CV death, non-fatal MI, and non-fatal stroke—the 
“canonical” CVD endpoints; some CV outcome trials 
include also heart failure, unstable angina requiring hos-
pitalization, amputation, and revascularization proce-
dures—the “hard” CVD endpoints [45].
It should be mentioned that the actual “FDA Guidance 
for Industry”, issued in 2008, is not requiring hospitaliza-
tion for HF as a primary/secondary outcome parameter.
In Saxagliptin Assessment of Vascular Outcomes 
Recorded in Patients with Diabetes Mellitus (SAVOR)—
Thrombolysis in Myocardial Infarction (TIMI) 53 
(SAVOR-TIMI 53) trial the major secondary endpoint 
was a composite of CV death, myocardial infarction (MI), 
stroke, hospitalization for unstable angina, coronary 
revascularization or HF. A total unexpected finding was 
the increased hospitalization for HF in T2D subjects on 
saxagliptin versus placebo (HR 1.27, 95 % CI 1.07–1.51, 
p = 0.007) [46].
In the primary publication of the Examination of Cardio-
vascular Outcomes with Alogliptin versus Standard of Care 
(EXAMINE) trial, despite the fact that 28 % of T2D subjects 
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had congestive HF at baseline, no information on HF out-
comes has been reported [47, 48]. Unfortunately, hospitali-
zation for HF was not planned as a stand-alone endpoint in 
the EXAMINE, so that a specific analysis on this outcome 
could not be reported in the primary publication. (Hos-
pitalization for heart failure 106 out of 2701 events in the 
alogliptin arm compared to 89 out of 2679 events in the 
placebo arm: HR 1.19, 95  % CI 0.89–1.58). In a post hoc 
analysis [49], there was a trend (p = NS) for increased hos-
pitalization for HF with alogliptin versus placebo. The fact 
that the trend toward increase of hospitalizations for HF in 
the overall cohort was not statistically significant is not sur-
prising, considering the relatively small sample size of sub-
jects in this trial. However, in the same study, an increased 
hospitalization for HF has been reported in patients with-
out a previous history of HF treated with alogliptin, but not 
in patients with a previous history of HF [49]. Standl and 
Schnell show the limitation of this post hoc analysis (dif-
ferent composite endpoints) and point out the similarities 
between SAVOR TIMI 53 and EXAMINE (in both studies, 
in patients without history of HF and treated with DPP4i 
the rate of HF was increased) [50]. In addition, vildagliptin 
in ventricular dysfunction diabetes (VIVIDD) trial, showed 
an unanticipated rise in left ventricular end-diastolic vol-
ume, end-systolic volume, and cardiac stroke volume [50]. 
On the other hand, while an increase of HF has been also 
reported with sitagliptin use [51], no increase in the inci-
dence of hospitalization for HF was observed with sitag-
liptin in the trial evaluating cardiovascular outcomes with 
sitagliptin (TECOS) trial [52, 53], or with incretin therapy 
in a recent observational study with a large cohort of T2D 
patients [54]. Noteworthy, the T2D population included 
in each of these outcome trials was different: if in TECOS, 
these subjects were with an established CVD, in SAVOR 
TIMI they had a history or were at risk for CVD and 
lastly, in EXAMINE they had an acute coronary syndrome 
within the previous 15–90 days [46, 47, 52]. This fact might 
(partly) explain the different results on the hospitalization 
for HF. Anyhow, recently the AHA stated that this could be 
a class effect [55].
Surprisingly, the EMPA-REG study with empagliflozin, 
a SGLT-2i, showed a CV protective effect of this com-
pound [56]. Apart the osmotic diuresis, there are proposed 
many other mechanisms behind CV protection of SGLT2i: 
improved insulin sensitivity, decreased blood pressure 
and arterial stiffness, body weight and visceral adiposity, 
decreased inflammation and oxidative stress [40].
Both results of CVOT on hospitalization for HF in T2D 
unfavorable with saxagliptin in SAVOR-TIMI 53 and 
favorable ones with empagliflozin in EMPA-REG might 
be explained, at least in part, by their impact on glucagon 
levels: DPP-4i reduce, and SGLT-2i increase, glucagon 
levels [57].
The reduced risk of hospitalization for heart failure 
with empagliflozin [56], which is present in patients with 
and without baseline heart failure [58], might be partly 
explained by a direct enhancement of myocardial func-
tion, determined by the increased levels of glucagon, and 
by its natriuretic effect. In addition, the beneficial effect 
of glucagon on disturbances of cardiac rhythm could be 
partly responsible for the reduction of CV mortality with 
empagliflozin. Conversely, the reduction of glucagon lev-
els during treatment with DPP4i could precipitate HF 
in individuals with unstable hemodynamic compensa-
tion. Indeed, in SAVOR-TIMI 53 the increased risk for 
hospitalization for HF with saxagliptin was observed in 
patients with the highest N-terminal pro B-type natriu-
retic peptide quartile and in those with chronic kidney 
disease [59], a trend confirmed also in the EXAMINE 
[49], while no data on N-terminal pro B-type natriuretic 
peptide are available for the TECOS.
Furthermore, the protective effects on diabetic kid-
ney disease of empagliflozin [60] could also be partly 
explained by the increase of glucagon, considering its 
effects on the kidney described before.
It has been shown that GLP-1 RA have an insulino-
tropic and glucagonostatic effect [32, 34]. However, the 
data regarding GLP-1RA and glucagon need to be more 
clarified: recently, in the LIBRA trial it has been demon-
strated that long-term treatment with liraglutide in early 
T2D has been associated with an increased post-chal-
lenge glucagonemia [35], while for Albiglutide the evi-
dence is that it does not affect glucagon secretion during 
hypoglycemia [36]. Liraglutide reduced the cardiovas-
cular mortality in the LEADER trial, but with a neutral 
effect on HF [61]. Both liraglutide and albiglutide were 
also not effective in improving HF in two recent trials in 
type 2 diabetes with advanced HF [62, 63]. At the state of 
the art, in our opinion, a possible involvement of gluca-
gon in the results on the mortality of the LEADER trial 
cannot be either claimed or excluded.
Conclusions
The glucagon inotropic action in human heart is well rep-
resented in not failing heart, but progressively declines in 
the failing heart, becoming undetectable in severe heart 
failure condition [13]. Therefore, the plasma levels of 
glucagon may contribute to maintain the heart function 
when the HF is not severe, which is the case of people 
recruited in the studies we mentioned. This means that 
glucagon might be very important for the heart and car-
diovascular system in type 2 diabetes. This is a paradox, 
considering that this hormone has been always consid-
ered harmful in diabetes. Future studies are needed to 
endorse or not the role of glucagon on heart, and may be 
also on kidney, in T2D.
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